FI972793A0 - Nebivololin käyttö antiaterogeenisenä aineena - Google Patents

Nebivololin käyttö antiaterogeenisenä aineena

Info

Publication number
FI972793A0
FI972793A0 FI972793A FI972793A FI972793A0 FI 972793 A0 FI972793 A0 FI 972793A0 FI 972793 A FI972793 A FI 972793A FI 972793 A FI972793 A FI 972793A FI 972793 A0 FI972793 A0 FI 972793A0
Authority
FI
Finland
Prior art keywords
nebivolol
alpha
antiatherogenic
agent
antiatherogenic agent
Prior art date
Application number
FI972793A
Other languages
English (en)
Swedish (sv)
Other versions
FI972793L (fi
FI118884B (fi
Inventor
Chaffoy De Courcelles Didie De
Anne Simone Josephine Lesage
Josepha Eduarda Maria F Leysen
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of FI972793L publication Critical patent/FI972793L/fi
Publication of FI972793A0 publication Critical patent/FI972793A0/fi
Application granted granted Critical
Publication of FI118884B publication Critical patent/FI118884B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pyrane Compounds (AREA)
FI972793A 1994-12-28 1997-06-27 Nebivololin käyttö antiaterogeenisenä aineena FI118884B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP94203775 1994-12-28
EP94203775 1994-12-28
PCT/EP1995/005174 WO1996019987A1 (en) 1994-12-28 1995-12-21 Use of nebivolol as an anti-atherogenic
EP9505174 1995-12-21

Publications (3)

Publication Number Publication Date
FI972793L FI972793L (fi) 1997-06-27
FI972793A0 true FI972793A0 (fi) 1997-06-27
FI118884B FI118884B (fi) 2008-04-30

Family

ID=8217503

Family Applications (1)

Application Number Title Priority Date Filing Date
FI972793A FI118884B (fi) 1994-12-28 1997-06-27 Nebivololin käyttö antiaterogeenisenä aineena

Country Status (20)

Country Link
US (2) US5874461A (fi)
EP (1) EP0801564B1 (fi)
JP (1) JPH10511655A (fi)
KR (1) KR100264348B1 (fi)
CN (1) CN1167418C (fi)
AT (1) ATE214924T1 (fi)
AU (1) AU700364B2 (fi)
CA (1) CA2207333C (fi)
CZ (1) CZ287513B6 (fi)
DE (1) DE69526120T2 (fi)
DK (1) DK0801564T3 (fi)
ES (1) ES2176354T3 (fi)
FI (1) FI118884B (fi)
HU (1) HU226208B1 (fi)
NO (1) NO315687B1 (fi)
NZ (1) NZ298074A (fi)
PT (1) PT801564E (fi)
SI (1) SI0801564T1 (fi)
SK (1) SK282144B6 (fi)
WO (1) WO1996019987A1 (fi)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT801564E (pt) * 1994-12-28 2002-09-30 Janssen Pharmaceutica Nv Utilizacao de nebivolol como agente anti-aterogernico
DE19716120A1 (de) * 1997-04-17 1998-10-22 Europ Lab Molekularbiolog Verwendung von cholesterinsenkenden Mitteln
US6713651B1 (en) 1999-06-07 2004-03-30 Theravance, Inc. β2-adrenergic receptor agonists
US6362371B1 (en) 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
JP2000207219A (ja) * 1999-01-18 2000-07-28 Fujitsu Ten Ltd 車載端末とセンタ―との間の通信システム、及び、通信システムに使用する車載端末
US6683115B2 (en) 1999-06-02 2004-01-27 Theravance, Inc. β2-adrenergic receptor agonists
US6593497B1 (en) 1999-06-02 2003-07-15 Theravance, Inc. β2-adrenergic receptor agonists
UA73965C2 (en) 1999-12-08 2005-10-17 Theravance Inc b2 ADRENERGIC RECEPTOR ANTAGONISTS
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
SI1413331T1 (sl) 2001-01-26 2008-02-29 Schering Corp Kombinacije fenofibrata peroksisomskega proliferator aktivirajocega receptorja (PPAR) z ezetimib zaviralcem absorpcije sterola za vaskularne indikacije
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
JP4711600B2 (ja) 2001-01-26 2011-06-29 シェーリング コーポレイション シトステロール血症の処置のための置換アゼチジノン化合物の使用
ATE437637T1 (de) * 2001-05-02 2009-08-15 Nitromed Inc Nitrosiertes und nitrosyliertes nebivolol und seine metaboliten, zusammensetzungen und anwendungsverfahren
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US7132415B2 (en) 2001-09-21 2006-11-07 Schering Corporation Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
WO2004042353A2 (en) * 2002-10-30 2004-05-21 Galileo Pharmaceuticals, Inc. Identifying therapeutic compounds based on their physical-chemical properties
CA2504878A1 (en) 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorption inhibitors for the treatment of demyelination
JP4589919B2 (ja) 2003-03-07 2010-12-01 シェーリング コーポレイション 高コレステロール血症の処置のための、置換アゼチジノン化合物、これらの処方物および使用
CN100439361C (zh) 2003-03-07 2008-12-03 先灵公司 取代的2-吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
CN1756755A (zh) 2003-03-07 2006-04-05 先灵公司 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
ITTO20030140U1 (it) * 2003-09-16 2005-03-17 Interfila Srl Matita cosmetica
US20050065099A1 (en) 2003-09-19 2005-03-24 Gail Walkinshaw Treatment of mitochondrial diseases
US7803838B2 (en) 2004-06-04 2010-09-28 Forest Laboratories Holdings Limited Compositions comprising nebivolol
US7838552B2 (en) 2004-06-04 2010-11-23 Forest Laboratories Holdings Limited Compositions comprising nebivolol
BRPI0513672A (pt) 2004-07-30 2008-05-13 Torrent Pharmaceuticals Limita processo aperfeiçoado para a preparação de 2h-1-benzopiran-2metanol, (alfa). (alfa)' [iminobis (metileno)] bis [6-fluoro-3, 4-dihidro, [2r* [r* [r* (s*)]]]], composição farmacêutica, forma t1 amorfa, e processo para a preparação da forma t1 de hidrocloreto de nebivolol
WO2006083779A2 (en) * 2005-01-31 2006-08-10 Mylan Laboratories, Inc. Pharmaceutical composition comprising hydroxylated nebivolol
PT2471530T (pt) 2005-06-01 2017-04-19 Edison Pharmaceuticals Inc Produtos terapêuticos com atividade redox para o tratamento de doenças mitocondriais e de outras condições e modulação de biomarcadores energéticos
EP1986636B1 (en) 2006-02-22 2013-04-24 Edison Pharmaceuticals, Inc. Phenol and 1,4-benzoquinone derivatives for use in the treatment of mitochondrial diseases
EP3456707B1 (en) 2007-11-06 2020-04-15 PTC Therapeutics, Inc. 4- (p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases
WO2009091777A1 (en) * 2008-01-15 2009-07-23 Forest Laboratories Holdings Limited Nebivolol in the treatment of sexual dysfunction
EP2262508B1 (en) 2008-03-05 2018-10-03 BioElectron Technology Corporation SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES
US8314153B2 (en) 2008-09-10 2012-11-20 Edison Pharmaceuticals, Inc. Treatment of pervasive developmental disorders with redox-active therapeutics
EP2362726B1 (en) 2008-10-14 2018-08-08 Bioelectron Technology Corporation Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells
AU2009327411A1 (en) * 2008-12-19 2010-06-24 Merck Sharp & Dohme Corp. Feed supplement for mammalian cell culture and methods of use
PL2424495T3 (pl) 2009-04-28 2018-06-29 Bioelectron Technology Corporation Leczenie dziedzicznej neuropatii nerwów wzrokowych lebera i dominującego zaniku nerwu wzrokowego chinonami tokotrienolu
CN103037839A (zh) * 2010-06-04 2013-04-10 全球药物科技有限公司 含有矫味剂的口服美其敏水性制剂
US9868711B2 (en) 2013-03-15 2018-01-16 Bioelectron Technology Corporation Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders
US9670170B2 (en) 2013-03-15 2017-06-06 Bioelectron Technology Corporation Resorufin derivatives for treatment of oxidative stress disorders
US9296712B2 (en) 2013-03-15 2016-03-29 Edison Pharmaceuticals, Inc. Resorufin derivatives for treatment of oxidative stress disorders
DE102014107132A1 (de) 2014-05-20 2015-11-26 Corden Pharma International Gmbh Verfahren zur Herstellung von Epoxiden die in der Herstellung von Nebivolol und dessen Derivaten einsetzbar sind
WO2016062265A1 (zh) * 2014-10-24 2016-04-28 朗齐生物医学股份有限公司 莫诺苯宗药物在用于制备治疗癌症的医药组合物中的用途
BR112017012988B1 (pt) 2014-12-16 2023-10-03 Ptc Therapeutics, Inc Formas polimoráficas e amorfas de (r)-2-hidroxi-2- metil-4- (2,4,5-trimetil-3,6-dioxociclohexa-1,4-dienil) butanamida
WO2017106803A1 (en) 2015-12-17 2017-06-22 Bioelectron Technology Corporation Flouroalkyl, flouroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1337432C (en) * 1988-03-23 1995-10-24 Raymond M. Xhonneux Method of lowering the blood pressure
TW355683B (en) * 1994-02-17 1999-04-11 Janssen Pharmaceutica Nv Composition containing micronized nebivolol
PT801564E (pt) * 1994-12-28 2002-09-30 Janssen Pharmaceutica Nv Utilizacao de nebivolol como agente anti-aterogernico

Also Published As

Publication number Publication date
EP0801564B1 (en) 2002-03-27
AU700364B2 (en) 1999-01-07
FI972793L (fi) 1997-06-27
CZ191997A3 (cs) 1999-01-13
HUT77927A (hu) 1998-11-30
NO972980L (no) 1997-06-26
MX9704669A (es) 1997-09-30
NZ298074A (en) 2001-01-26
CN1171739A (zh) 1998-01-28
SI0801564T1 (en) 2002-08-31
NO972980D0 (no) 1997-06-26
KR100264348B1 (ko) 2000-08-16
CZ287513B6 (en) 2000-12-13
DE69526120D1 (de) 2002-05-02
DK0801564T3 (da) 2002-07-15
SK85697A3 (en) 2000-04-10
HU226208B1 (en) 2008-06-30
WO1996019987A1 (en) 1996-07-04
CA2207333A1 (en) 1996-07-04
DE69526120T2 (de) 2002-11-28
SK282144B6 (sk) 2001-11-06
ATE214924T1 (de) 2002-04-15
US5874461A (en) 1999-02-23
NO315687B1 (no) 2003-10-13
ES2176354T3 (es) 2002-12-01
CN1167418C (zh) 2004-09-22
AU4347796A (en) 1996-07-19
JPH10511655A (ja) 1998-11-10
PT801564E (pt) 2002-09-30
EP0801564A1 (en) 1997-10-22
FI118884B (fi) 2008-04-30
CA2207333C (en) 2006-10-17
US6075046A (en) 2000-06-13

Similar Documents

Publication Publication Date Title
FI972793A0 (fi) Nebivololin käyttö antiaterogeenisenä aineena
DE69920757D1 (de) Immunsuppressive wirkungen von pteridinderivaten
HUP9700603A1 (hu) Gyógyászati készítmény véralvadási zavarok kezelésére
CA2272584A1 (en) Novel substituted pyrazole derivatives for the treatment of cardiocirculatory diseases
TR199901174T2 (xx) Yeni heterosiklilmetil-ikameli pirazol t�revleri.
ATE334668T1 (de) Pharmazeutische zusammensetzung zur behandlung von neurologischen und neuropsychiatrischen erkrankungen
IL110943A (en) Compositions comprising an inhibitor of cholesterol synthesis for the treatment of skin disorders
PT998287E (pt) Utilizacao de levobupivacaina
ATE201992T1 (de) Carbostyrilderivat zur behandlung von ophthalmologischen erkrankungen
DE69725879D1 (de) VERWENDUNG VON p-AMINOPHENOLDERIVATEN ZUR HERSTELLUNG VON PHARMAZEUTISCHEN ZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON NEURODEGENERATIVEN ERKRANKUNGEN
DE59904180D1 (de) Cyclopentabenzofuran-derivate und ihre verwendung
BRPI0408889A (pt) uso de clusterina para o tratamento e/ou prevenção de doenças neurológicas periféricas
BG104179A (en) Phanquinon administration for the treatment of the alzheimer's disease
BG102667A (en) Diosgenine-containing composition
AU1278600A (en) Novel therapeutic application of nicergoline
EA199700243A1 (ru) Производное аминотетралина для лечения сердечно-сосудистых заболеваний
NO984651D0 (no) Anvendelse av benzonaftalenderivater for fremstilling av medikamenter for behandling av sykdommer i sentralnervesystemet
PT869785E (pt) 4-hidroxicumarina-3-carboxamidas para o tratamento de diabetes mellitus nao insulinodependente
AU1569700A (en) Novel therapeutic application of low molecular weight heparin
DE69930419D1 (de) Verwendung von menschliche protein c zur herstellung eines arzneimittels zur behandlung von heparininduzierter thrombozytopenie
TR200003352T2 (tr) Yeni pentaerythrit türevleri, bunların imalatı ve kullanımları ile bunların sentezi için ara maddeler
WO1999021538A3 (de) Verwendung von glykosaminoglykanen zur herstellung von pharmazeutischen zubereitungen zur behandlung von mit diabetes assoziierten augenkrankheiten
NO984198L (no) FremgangsmÕte for behandling av aggresjon
AU1278700A (en) Novel therapeutic use of 1,6-dimethyl-8beta-hydroxymethyl-10alpha-methoxyergoline
UA33498A (uk) Спосіб лікування терапевтично резистентних форм шизофренії

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 118884

Country of ref document: FI

MA Patent expired